Clinical Trials Directory

Trials / Completed

CompletedNCT00088101

STA-5312 Administered on Alternate Weekdays Every Two Weeks to Patients With Hematologic Malignancies and Patients With Solid Tumors

Phase I Trial of STA-5312 Administered on Alternate Weekdays Every Two Weeks to Patients With Hematological Malignancies and Patients With Solid Tumors

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
42 (planned)
Sponsor
Synta Pharmaceuticals Corp. · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to determine the safety, toxicity and patient tolerance of STA-5312 administered intravenously to patients with relapsed or refractory hematological malignancies and patients with solid tumors.

Conditions

Interventions

TypeNameDescription
DRUGSTA-5312

Timeline

Start date
2004-02-01
Completion
2004-12-01
First posted
2004-07-21
Last updated
2008-12-04

Locations

8 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT00088101. Inclusion in this directory is not an endorsement.